Antibody drug cost-effective for allergic asthma

NEW YORK (Reuters Health) - The antibody drug omalizumab (Xolair) is cost-effective for treating allergic asthma that has not responded fully to steroid inhalers and other mediations, according to a report in the journal Allergy.

Continue to Antibody drug cost-effective for allergic asthma on Reuters Health eLine.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz